首页 > 最新文献

Journal Der Deutschen Dermatologischen Gesellschaft最新文献

英文 中文
One-stage inferiorly based transposition dorsum/lateral nasal flap in nasal ala reconstruction.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-17 DOI: 10.1111/ddg.15635
Pedro Redondo, Justin Gabriel Schlager, Alejandra Tomás-Velázquez
{"title":"One-stage inferiorly based transposition dorsum/lateral nasal flap in nasal ala reconstruction.","authors":"Pedro Redondo, Justin Gabriel Schlager, Alejandra Tomás-Velázquez","doi":"10.1111/ddg.15635","DOIUrl":"https://doi.org/10.1111/ddg.15635","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
History, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross-sectional study.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-16 DOI: 10.1111/ddg.15610
Neda Cramer, Daniel Kromer, Julia M Bootsveld, Sabine Sennhenn-Kirchner, Sascha Gerdes, Wiebke Sondermann, Katharina Assaf, Matthias Goebeler, Dagmar Wilsmann-Theis, Claudia Günther, Christian Kromer, Rotraut Mössner

Background and objectives: Mucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging.

Patients and methods: In this cross-sectional study, a wide range of characteristics of the patient's journey were assessed and evaluated from a total of 72 patients with mucosal LP who were treated in the dermatology departments of six German university medical centers between 02/2022 and 07/2023.

Results: On average, 18.1 months elapsed between the onset of symptoms and diagnosis. Until the correct diagnosis was made, an average of 3.1 different physicians of the same or different specialties were consulted. 28.1% of patients also had cutaneous involvement. Therapeutically, 68% of patients received at least one systemic drug. Both topical (90%, 65/72) and systemic (oral, 50% of patients, 36/72; intravenous, 33%, 24/72) glucocorticoids were most frequently used. Systemic agents were most often discontinued due to ineffectiveness (46%, 50/110). Satisfaction with treatment was highest for intravenous and topical glucocorticoids (moderate to high satisfaction: 59% and 36%, respectively), and lowest for retinoids with 8%.

Conclusions: This study indicates that there might be a lack of diagnostic awareness among physicians and the unmet need for effective systemic treatment options.

{"title":"History, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross-sectional study.","authors":"Neda Cramer, Daniel Kromer, Julia M Bootsveld, Sabine Sennhenn-Kirchner, Sascha Gerdes, Wiebke Sondermann, Katharina Assaf, Matthias Goebeler, Dagmar Wilsmann-Theis, Claudia Günther, Christian Kromer, Rotraut Mössner","doi":"10.1111/ddg.15610","DOIUrl":"https://doi.org/10.1111/ddg.15610","url":null,"abstract":"<p><strong>Background and objectives: </strong>Mucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging.</p><p><strong>Patients and methods: </strong>In this cross-sectional study, a wide range of characteristics of the patient's journey were assessed and evaluated from a total of 72 patients with mucosal LP who were treated in the dermatology departments of six German university medical centers between 02/2022 and 07/2023.</p><p><strong>Results: </strong>On average, 18.1 months elapsed between the onset of symptoms and diagnosis. Until the correct diagnosis was made, an average of 3.1 different physicians of the same or different specialties were consulted. 28.1% of patients also had cutaneous involvement. Therapeutically, 68% of patients received at least one systemic drug. Both topical (90%, 65/72) and systemic (oral, 50% of patients, 36/72; intravenous, 33%, 24/72) glucocorticoids were most frequently used. Systemic agents were most often discontinued due to ineffectiveness (46%, 50/110). Satisfaction with treatment was highest for intravenous and topical glucocorticoids (moderate to high satisfaction: 59% and 36%, respectively), and lowest for retinoids with 8%.</p><p><strong>Conclusions: </strong>This study indicates that there might be a lack of diagnostic awareness among physicians and the unmet need for effective systemic treatment options.</p>","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
UV-induced fluorescence dermatoscopy in a case of porokeratosis ptychotropica.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-14 DOI: 10.1111/ddg.15669
Bengu Nisa Akay, Gizem Nur Ozturk, Sule Altiner, Hatice Sanli
{"title":"UV-induced fluorescence dermatoscopy in a case of porokeratosis ptychotropica.","authors":"Bengu Nisa Akay, Gizem Nur Ozturk, Sule Altiner, Hatice Sanli","doi":"10.1111/ddg.15669","DOIUrl":"https://doi.org/10.1111/ddg.15669","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-13 DOI: 10.1111/ddg.15638
Jasper N Pruessmann, Wiebke Pruessmann, Christian D Sadik

Immune checkpoint receptors and ligands such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) and ligand-1 (PD-L1) are widely expressed on immune and non-immune cells and fine tune the activation level of immune cells, thus, enabling, preventing, or terminating immune responses. Blockade of CTLA-4, PD-1 or PD-L1 by checkpoint inhibitors (CIs), unleashing immune responses, has become a mainstay in the treatment of diverse types of cancer. The induction of autoinflammatory, yet unspecific tissue damage in diverse organs is called an immune related adverse event (irAE), a class side-effect of CIs and may require the discontinuation of immunotherapy. Among frequent skin rashes, CIs targeting the PD-L1/PD-1 axis can elicit the IgG autoantibody- and granulocyte-driven bullous pemphigoid (BP) in about 0.3% to 0.6% of treated patients. Pathogenesis of BP requires a complex cellular inflammatory response after anti-BP180 autoantibody binding to the dermal epidermal junction. The prevalence of autoantibodies against BP180 in healthy blood donors of approximately 0.52% equals the prevalence of irBP among treated cancer patients, underlining the potential relevance of the PD-1 mediated regulation of tissue inflammation for spontaneous BP. If skin rashes appear during CI therapy, biopsies should be taken and examined by histopathological and direct immunofluorescence microscopy.

{"title":"Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis.","authors":"Jasper N Pruessmann, Wiebke Pruessmann, Christian D Sadik","doi":"10.1111/ddg.15638","DOIUrl":"https://doi.org/10.1111/ddg.15638","url":null,"abstract":"<p><p>Immune checkpoint receptors and ligands such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) and ligand-1 (PD-L1) are widely expressed on immune and non-immune cells and fine tune the activation level of immune cells, thus, enabling, preventing, or terminating immune responses. Blockade of CTLA-4, PD-1 or PD-L1 by checkpoint inhibitors (CIs), unleashing immune responses, has become a mainstay in the treatment of diverse types of cancer. The induction of autoinflammatory, yet unspecific tissue damage in diverse organs is called an immune related adverse event (irAE), a class side-effect of CIs and may require the discontinuation of immunotherapy. Among frequent skin rashes, CIs targeting the PD-L1/PD-1 axis can elicit the IgG autoantibody- and granulocyte-driven bullous pemphigoid (BP) in about 0.3% to 0.6% of treated patients. Pathogenesis of BP requires a complex cellular inflammatory response after anti-BP180 autoantibody binding to the dermal epidermal junction. The prevalence of autoantibodies against BP180 in healthy blood donors of approximately 0.52% equals the prevalence of irBP among treated cancer patients, underlining the potential relevance of the PD-1 mediated regulation of tissue inflammation for spontaneous BP. If skin rashes appear during CI therapy, biopsies should be taken and examined by histopathological and direct immunofluorescence microscopy.</p>","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin lesions after hematopoietic stem cell transplantation: Graft-versus-host disease versus true dermatomyositis.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-13 DOI: 10.1111/ddg.15681
Alba Calleja Algarra, Borja González Rodriguez, Jon Fulgencio Barbarin, Fátima Tous Romero, Virginia Velasco Tamariz, Lorena Calderón Lozano, Pablo Luis Ortiz-Romero, Carlos Zarco Olivo
{"title":"Skin lesions after hematopoietic stem cell transplantation: Graft-versus-host disease versus true dermatomyositis.","authors":"Alba Calleja Algarra, Borja González Rodriguez, Jon Fulgencio Barbarin, Fátima Tous Romero, Virginia Velasco Tamariz, Lorena Calderón Lozano, Pablo Luis Ortiz-Romero, Carlos Zarco Olivo","doi":"10.1111/ddg.15681","DOIUrl":"https://doi.org/10.1111/ddg.15681","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete response of a metastatic cutaneous apocrine carcinoma under oral S-1 monotherapy.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-11 DOI: 10.1111/ddg.15652
Shoichiro Ishizuki, Yoshiyuki Nakamura, Ko Matsuoka, Yasuhiro Fujisawa, Toshifumi Nomura
{"title":"Complete response of a metastatic cutaneous apocrine carcinoma under oral S-1 monotherapy.","authors":"Shoichiro Ishizuki, Yoshiyuki Nakamura, Ko Matsuoka, Yasuhiro Fujisawa, Toshifumi Nomura","doi":"10.1111/ddg.15652","DOIUrl":"https://doi.org/10.1111/ddg.15652","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zinc deficiency-associated dermatitis in a prematurely born infant.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-07 DOI: 10.1111/ddg.15637
Jennifer Grötsch, Michael Sticherling
{"title":"Zinc deficiency-associated dermatitis in a prematurely born infant.","authors":"Jennifer Grötsch, Michael Sticherling","doi":"10.1111/ddg.15637","DOIUrl":"https://doi.org/10.1111/ddg.15637","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tattoo-induced hypertrophic discoid lupus erythematosus in a patient with vitiligo.
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-07 DOI: 10.1111/ddg.15670
Yuan-Yu Hong, I-Jung Hsieh, Sui-Qing Cai
{"title":"Tattoo-induced hypertrophic discoid lupus erythematosus in a patient with vitiligo.","authors":"Yuan-Yu Hong, I-Jung Hsieh, Sui-Qing Cai","doi":"10.1111/ddg.15670","DOIUrl":"https://doi.org/10.1111/ddg.15670","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erwerbstätigkeit, Arbeitsfähigkeit und Krankenstand bei Patienten mit Melanom im ersten Jahr nach der Diagnose
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-06 DOI: 10.1111/ddg.15560_g
Susanne Dugas-Breit, Martin Dugas, Hans-Joachim Schulze
<p>Das maligne Melanom der Haut galt noch vor wenigen Jahrzehnten als seltener Tumor, belegte jedoch im Jahr 2015 in Deutschland den fünften Platz der häufigsten soliden Tumorentitäten sowohl bei Männern als auch bei Frauen.<span><sup>1</sup></span> Das Melanom als Hauttumor mit der höchsten Metastasierungsrate ist für mehr als 90% aller Todesfälle durch Hauttumoren verantwortlich. Eine Analyse der Inzidenz in Australien, Neuseeland, Norwegen, Schweden, Großbritannien sowie der weißen Bevölkerung der USA von 1982 bis 2011 ergab einen deutlichen Anstieg von etwa 3% jährlich.<span><sup>2</sup></span> In Deutschland stieg die altersstandardisierte Inzidenzrate im Zeitraum von 1970 bis 2016 von drei auf 21 Fälle pro 100 000 Einwohner und Jahr. Das mediane Erkrankungsalter lag 2020 für Frauen bei 63 Jahren und für Männer bei 69 Jahren.<span><sup>1</sup></span> Die Altersverteilung zeigt zwei Gipfel: Junge Erwachsene bis etwa 30 Jahre sowie ältere Personen über 50 Jahre erkranken besonders häufig am Melanom. Bei Frauen zwischen 20 und 30 Jahren ist das Melanom die häufigste Krebsart in Deutschland, noch häufiger als Brustkrebs.<span><sup>3</sup></span> Berufstätige sind daher besonders häufig von dieser Erkrankung betroffen.<span><sup>1, 4</sup></span></p><p>Im Jahr 2015 führte die Diagnose eines Melanoms bei 335 von 100 000 aktiv Versicherten in der gesetzlichen Rentenversicherung zur vorzeitigen Verrentung, davon waren 107 Personen unter 50 Jahre alt.<span><sup>5</sup></span> Daher stellt sich die Frage, ob die Neudiagnose eines Melanoms Auswirkungen auf die Arbeitsfähigkeit der Patienten hat. Bei einer umfangreichen Literaturrecherche mit den Suchbegriffen „workability“, „employment“, „occupation“ oder „sick leave“ konnten wir nur relativ wenige, schlecht vergleichbare Studien zu diesem Thema finden. Eine US-Studie aus dem Jahr 2012 ergab, dass jährlich 3,31 Millionen US-Arbeitnehmer an Krebs erkrankten, was zu etwa 33,4 Millionen Arbeitsunfähigkeitstagen führte. Das Melanom war hier im Vergleich zu anderen Krebsarten mit einer höheren Krankheitslast verbunden.<span><sup>6</sup></span></p><p>Entstellende oder funktionseinschränkende Operationen können zu körperlichen und psychischen Belastungen führen, ebenso wie Nebenwirkungen von Medikamenten. Die medizinische Rehabilitation von Patienten mit Melanom zielt darauf ab, körperliche, geistige, soziale und berufliche Beeinträchtigungen zu verhindern oder zu verringern und die soziale Teilhabe aufrechtzuerhalten. Weitere Ziele sind die Verbesserung der Lebensqualität und eine möglichst dauerhafte Wiedereingliederung in das Arbeitsleben,<span><sup>7</sup></span> also die Förderung der Arbeitsfähigkeit. Daher sind für komplexe onkologische Symptome nur interdisziplinäre Behandlungsstrategien geeignet. Die aktuelle Leitlinie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften zum Melanom<span><sup>7</sup></span> empfiehlt, Rehabilitationsmaßnahmen bereits im Rahmen der Primärver
{"title":"Erwerbstätigkeit, Arbeitsfähigkeit und Krankenstand bei Patienten mit Melanom im ersten Jahr nach der Diagnose","authors":"Susanne Dugas-Breit,&nbsp;Martin Dugas,&nbsp;Hans-Joachim Schulze","doi":"10.1111/ddg.15560_g","DOIUrl":"https://doi.org/10.1111/ddg.15560_g","url":null,"abstract":"&lt;p&gt;Das maligne Melanom der Haut galt noch vor wenigen Jahrzehnten als seltener Tumor, belegte jedoch im Jahr 2015 in Deutschland den fünften Platz der häufigsten soliden Tumorentitäten sowohl bei Männern als auch bei Frauen.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Das Melanom als Hauttumor mit der höchsten Metastasierungsrate ist für mehr als 90% aller Todesfälle durch Hauttumoren verantwortlich. Eine Analyse der Inzidenz in Australien, Neuseeland, Norwegen, Schweden, Großbritannien sowie der weißen Bevölkerung der USA von 1982 bis 2011 ergab einen deutlichen Anstieg von etwa 3% jährlich.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; In Deutschland stieg die altersstandardisierte Inzidenzrate im Zeitraum von 1970 bis 2016 von drei auf 21 Fälle pro 100 000 Einwohner und Jahr. Das mediane Erkrankungsalter lag 2020 für Frauen bei 63 Jahren und für Männer bei 69 Jahren.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Die Altersverteilung zeigt zwei Gipfel: Junge Erwachsene bis etwa 30 Jahre sowie ältere Personen über 50 Jahre erkranken besonders häufig am Melanom. Bei Frauen zwischen 20 und 30 Jahren ist das Melanom die häufigste Krebsart in Deutschland, noch häufiger als Brustkrebs.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Berufstätige sind daher besonders häufig von dieser Erkrankung betroffen.&lt;span&gt;&lt;sup&gt;1, 4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Im Jahr 2015 führte die Diagnose eines Melanoms bei 335 von 100 000 aktiv Versicherten in der gesetzlichen Rentenversicherung zur vorzeitigen Verrentung, davon waren 107 Personen unter 50 Jahre alt.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Daher stellt sich die Frage, ob die Neudiagnose eines Melanoms Auswirkungen auf die Arbeitsfähigkeit der Patienten hat. Bei einer umfangreichen Literaturrecherche mit den Suchbegriffen „workability“, „employment“, „occupation“ oder „sick leave“ konnten wir nur relativ wenige, schlecht vergleichbare Studien zu diesem Thema finden. Eine US-Studie aus dem Jahr 2012 ergab, dass jährlich 3,31 Millionen US-Arbeitnehmer an Krebs erkrankten, was zu etwa 33,4 Millionen Arbeitsunfähigkeitstagen führte. Das Melanom war hier im Vergleich zu anderen Krebsarten mit einer höheren Krankheitslast verbunden.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Entstellende oder funktionseinschränkende Operationen können zu körperlichen und psychischen Belastungen führen, ebenso wie Nebenwirkungen von Medikamenten. Die medizinische Rehabilitation von Patienten mit Melanom zielt darauf ab, körperliche, geistige, soziale und berufliche Beeinträchtigungen zu verhindern oder zu verringern und die soziale Teilhabe aufrechtzuerhalten. Weitere Ziele sind die Verbesserung der Lebensqualität und eine möglichst dauerhafte Wiedereingliederung in das Arbeitsleben,&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; also die Förderung der Arbeitsfähigkeit. Daher sind für komplexe onkologische Symptome nur interdisziplinäre Behandlungsstrategien geeignet. Die aktuelle Leitlinie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften zum Melanom&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; empfiehlt, Rehabilitationsmaßnahmen bereits im Rahmen der Primärver","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"23 2","pages":"151-160"},"PeriodicalIF":5.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ddg.15560_g","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-Omics Analysen bei Plaque-Psoriasis – Neue Wege gehen
IF 5.5 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-06 DOI: 10.1111/ddg.15650_g
Thomas Graier
{"title":"Multi-Omics Analysen bei Plaque-Psoriasis – Neue Wege gehen","authors":"Thomas Graier","doi":"10.1111/ddg.15650_g","DOIUrl":"https://doi.org/10.1111/ddg.15650_g","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"23 2","pages":"279-280"},"PeriodicalIF":5.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal Der Deutschen Dermatologischen Gesellschaft
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1